2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Simpson Biotech Co., Ltd. 善笙

Company Presentations

Friday, July 24 Company Presentations 5–Diagnostics, Device, NPO

Simpson Biotech Co., Ltd. 善笙

Company Info

Name /Simpson Biotech Co., Ltd. 善笙

Address /#1-1, Wenming 2nd St., Guishan, Taoyuan City, Taiwan

Website /www.simpsonbiotech.com

Presenter

Name /Mr. Chia-Chin Sheu

Title /President

Email /service@simpsonbiotech.com

Telephone /(Work) +886-3-396-3466

Fax /+886-3-396-3407

Mobile /

Company Type

Biotechnology

About the Company

Simpson Biotech Co., Ltd.(SBC),established in 1998, is a privately held company located in Taipei focusing on 1>. The fermentation of medicinal fungus and the enzymatic hydrolysis of natural ingredients for dietary supplements (glycemic index reduction, blood sugar control, immune regulation, IFNγ stimulant) and early stage drug discovery (preventing or treating NAFLD/NASH, anti-inflammation). 2>. The development and the fermentation of recombinant proteins and industrial enzymes using patented proteins purification platform. 3>. The establishment of unique bioconversion process for production of bio-functional oligosaccharides or water soluble chitosan for anti-virus/yeast/bacteria. Simpson Biotech has won numerous awards and holds more than 52 issued patents.

Brief Description of main products or services

  • Dream compound as total solution for NAFLD/NASH

 

NAFLD/NASH(Non-Alcoholic Fatty Liver Disease / Non-Alcoholic Steatohepatitis) is a condition when excess lipid accumulated in liver without significant alcohol consumption and became the major common cause of liver disease in Western countries.  NAFLD is closely related to metabolic syndromes including obesity, diabetics and excess fat in liver cause hepatic steatosis to steatohepatitis (NASH) with significant inflammation and progressive fibrosis. Liver fibrosis may further become cirrhosis and hepatocellular carcinoma(HCC) and NASH related liver transplantation has dramatically increased.

 

Antrodin is a natural compound as oral drug effective for whole progress of NAFLD/NASH with comprehensive global patent protection including compound, applications, indications, metabolites:

(1)   Prevention of non-alcohol fatty liver formation and metabolic syndromes:

Reduce the triglyceride and cholesterol level in both liver and serum

Decrease the lipid deposition in liver

Reduce blood glucose

(2)   Prevention and reverse of NASH, Liver Fibrosis, Liver Cirrhosis

Reduce NAFLD/NASH indexes (liver oil, ALT, AST, TG, CHL, blood glucose) in disease animal

Anti-inflammation at nM level, improve inflammation factors

Reduce oxidative stress to improve liver cell damage

Anti-liver fibrosis/cirrhosis

(3)   Liver generation improvement after liver transplantation

 

Looking for cooperation partner for new drug development

Contact Person

Name /Ms. Evelyn Wang

Email /service@simpsonbiotech.com

Phone /+886-3-396-3466